Relmada Therapeutics, (RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, has announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.
Relmada Therapeutics has announced the promotion of Michael D. Becker to chief financial officer
Mr. Becker joined Relmada in 2014 as senior vice president of finance and corporate
Michael Becker, the new chief financial officer of Relmada Therapeutics
development. In his new role, he will be responsible for all corporate finance and accounting activities for the company.
"We are pleased to expand Michael's role as we prepare for the continued growth and
expansion of our operations at Relmada," said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics. "Since joining the company in 2014, Michael has consistently managed responsibilities of expanding scope and complexity. As we advance our pipeline through several critical upcoming milestones, sound financial planning and discipline will be even more important elements of our success.
“Michael's outstanding experience in both the biotechnology and financial services sectors together with his deep understanding of our business make him uniquely suited to lead our finance team moving forward."